$EXEL
EXELIXIS, INC.
Runway:cash-flow +
NasdaqMarket cap: —CIK 0000939767
Upcoming catalysts
0 surfacedNo catalysts surfaced for EXEL yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05176483 | Zanzalintinib | Phase 1 | Recruiting | 2030-06-28 |
| NCT07620574 | cabozantinib | Phase 3 | Not Yet Recruiting | 2030-05-31 |
| NCT06943755 | Zanzalintinib | Phase 3 | Recruiting | 2029-06-01 |
| NCT05932862 | XL309 | Phase 1 | Recruiting | 2029-01-03 |
| NCT06082167 | Zanzalintinib | Phase 3 | Active Not Recruiting | 2028-08-01 |
| NCT07428616 | Zanzalintinib | Phase 2 | Recruiting | 2028-02-29 |
| NCT07123103 | XB371 | Phase 1 | Recruiting | 2027-11-01 |
| NCT06952010 | XB628 | Phase 1 | Recruiting | 2027-05-31 |
| NCT06545331 | XB010 | Phase 1 | Recruiting | 2026-11-23 |
| NCT03845166 | XL092 | Phase 1 | Active Not Recruiting | 2026-08-31 |
| NCT05425940 | XL092 | Phase 3 | Active Not Recruiting | 2026-05-01 |
| NCT06962332 | Zanzalintinib | Phase 1 | Recruiting | 2025-12-01 |
| NCT05678673 | XL092 | Phase 3 | Active Not Recruiting | 2025-07-01 |
| NCT06191796 | Zanzalintinib | Phase 1 | Terminated | 2025-05-12 |
| NCT06630247 | XL495 | Phase 1 | Terminated | 2025-05-07 |
| NCT04925284 | XB002 | Phase 1 | Completed | 2025-03-10 |
| NCT04726332 | XL102 | Phase 1 | Terminated | 2024-05-02 |
| NCT04446117 | cabozantinib | Phase 3 | Active Not Recruiting | 2024-04-19 |
| NCT03170960 | cabozantinib | Phase 1 | Active Not Recruiting | 2023-02-21 |
| NCT05144347 | XL114 | Phase 1 | Terminated | 2022-11-01 |